Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, DC-CIK Immunotherapy, and Hyperthermia in Advanced Malignant Mesothelioma
NCT03393858Phase 2Terminated
- Sponsor
- Capital Medical University
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Whole Cell Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, dendritic cell vaccine + cytokine-induced killer cells in malignant mesothelioma, sponsored by Capital Medical University. Started Dec 2017; status: terminated.
02
Drugs
pembrolizumabdendritic cell vaccine + cytokine-induced killer cells
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03393858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393858.